|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
39,646 |
$2,308,190.12 |
7.20% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,351 |
$2,264,788.83 |
7.06% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
9,953 |
$2,261,222.07 |
7.05% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
19,970 |
$2,239,835.20 |
6.99% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
10,655 |
$2,201,323.00 |
6.87% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
82,811 |
$1,245,477.44 |
3.88% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
6,445 |
$1,205,601.70 |
3.76% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
44,715 |
$1,177,345.95 |
3.67% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,582 |
$1,109,646.44 |
3.46% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
8,301 |
$1,092,826.65 |
3.41% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
9,431 |
$1,076,642.96 |
3.36% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,489 |
$1,055,136.88 |
3.29% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
3,185 |
$1,050,476.70 |
3.28% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
5,394 |
$1,053,124.56 |
3.28% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,824 |
$1,040,409.60 |
3.24% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,746 |
$759,389.12 |
2.37% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
7,659 |
$742,233.69 |
2.31% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
4,093 |
$555,747.54 |
1.73% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
11,505 |
$502,538.40 |
1.57% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
968 |
$404,178.72 |
1.26% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
6,099 |
$397,349.85 |
1.24% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,380 |
$394,556.40 |
1.23% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
2,944 |
$387,960.32 |
1.21% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
7,071 |
$382,258.26 |
1.19% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,601 |
$358,239.96 |
1.12% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
9,379 |
$313,071.02 |
0.98% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
12,227 |
$275,229.77 |
0.86% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
3,954 |
$274,486.68 |
0.86% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
5,708 |
$251,836.96 |
0.79% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
2,922 |
$218,594.82 |
0.68% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,624 |
$218,889.60 |
0.68% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
8,348 |
$214,376.64 |
0.67% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
7,368 |
$211,756.32 |
0.66% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
857 |
$194,916.08 |
0.61% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,651 |
$191,286.35 |
0.60% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
14,532 |
$186,445.56 |
0.58% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,847 |
$181,689.39 |
0.57% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,843 |
$177,904.79 |
0.55% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
7,377 |
$165,466.11 |
0.52% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
617 |
$164,146.68 |
0.51% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
5,876 |
$163,529.08 |
0.51% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,811 |
$158,643.60 |
0.49% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
2,095 |
$157,711.60 |
0.49% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
6,924 |
$151,981.80 |
0.47% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
511 |
$151,312.21 |
0.47% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,862 |
$150,282.02 |
0.47% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
6,305 |
$147,221.75 |
0.46% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
3,107 |
$148,669.95 |
0.46% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
3,174 |
$144,004.38 |
0.45% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,252 |
$143,272.24 |
0.45% |
| US Dollar |
$USD |
|
Other |
42,433 |
$42,433.28 |
0.13% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|